(BW)(NY-PALL)(PLL)颇尔公司在INTERPHEX2006上展示新技术，迎接药品生产挑战
INTERPHEX2006 第1825号展台
美国商业新闻2006年3月21日纽约州EAST HILLS消息——
随着生物科技企业与传统制药企业之间的界限越来越模糊，制定更有效的工艺开发战略与加强可伸缩技术变得越来越重要。有越来越多的生物科技企业正在从药品研发阶段步入临床试验与大规模药品生产阶段。大型制药企业继续增加它们在早期药品研发方面的研发投资。从研发进入大规模产品生产需要有创新的可伸缩技术，其操作需要能符合GMP规定。颇尔公司(Pall Corporation)（纽约证券交易所：PLL）在INTERPHEX2006上推出六种新技术，目的就是帮助这些日益整合的市场弥补研发与大规模生产之间的笨凇?br>
这些技术覆盖了研发与生产各个阶段所需的生物制药设备，具体包括：
——第一台全包含式过滤系统，能够安全处理高效的制药混合物；
——两台先进的混合消毒过滤器，能够加快基于高蛋白浓缩物的新疗法的下游处理速度；
——一台新型液压层析柱，能够自动在药品净化过程中自动维护与改进安全性；
——两台新工艺优化系统，能够使用少量蛋白质完成自动数据登录。
Pall BioPharmaceuticals Global总裁Ken Frank说道：“通过提供全流体解决方案，这些新技术能够帮助制药企业提高整个研发与生产流程的速度、安全性与效率。无论是在生产活性制药成分(API)期间保护工人安全，还是提高下游处理效率以及提高流程建模的成本效率，颇尔公司的新技术均能够解决当今的工艺处理难题。”
新产品简介
虽然生物科技企业在生产高蛋白浓缩物的上游工艺中已经取得了巨大进步，但是它们却在下流工艺上遇到了瓶颈，对于这些高浓度解决方案来说，标准的过滤技术在高流速下缺乏经济性。新推出的Supor(R) UEKV和Fluorodyne(R) EX高流速消毒级盒式过滤器能够解决这些问题，提供卓越的吞吐率，加快生产速度以及新一代蛋白质药品的上市时间。
颇尔公司同时还在色谱分离市场中发布了新创新技术。用来净化生物药品的传统柱色谱系统检修时间长，需要投入大量人力来拆机以完成日常保养，这从而降低了吞吐率。通过为自动化柱拆卸提供创新的液压起重装置，新推出的Pall Resolute(R) DAP柱色谱系统能够减少多达三分之二的日常维修时间。它能够大幅提高清洁度与改进操作安全性，为制造商带来像是供签约制药企业使用的灵活的多用途解决方案，对于签约制药企业来说，最重要的能在大批量生产期间为其提供快速安全的设备维护。
颇尔公司通过新推出的Minim(TM) II和Centramate(TM) 500切向流过滤(TFF)系统能够满足这一关键需求，提供价格上可以承受的测试设备，从而能够可靠地完成小批量生产。Minim II系统能够为实验室提供超小批量测试解决方案，从而决定真实的规模生产条件，这样就不用在药品研发过程中浪费大量宝贵的药品生产原料。Centramate 500系统将这一理念提高到了新水平，成为了药品研发的理想设备，处理容量最高可达5升。两种系统都能够优化工艺水平和减少开发时间。系统还能够提供自动数据登录，从而满足日益严格的监管要求。
随着制药净化工艺中开始使用新的高效活性制药成分(APIs)，针对有害的生物活性颗粒与催化剂的防护需求也开始不断增加。为了保护工人与周围环境不受这些危险混合物的影响，颇尔公司推出了GBK密封系统，这也是首款全集成手套式系统，能够安全进行密封和过滤。
颇尔公司将会于3月22日星期三下午12:30至2:00在INTERPHEX2006举行期间在1E02房间特别举行媒体午餐会推广其亚洲业务。Frank补充说道：“我们不断扩大自身的技术能力与地理覆盖范围，这反映出公司致力于帮助全球客户优化药品开发与生产流程，进而实现完全的商业化。”
关于颇尔公司(Pall Corporation)
颇尔公司(Pall Corporation)是快速发展的过滤、分离与净化领域中的全球性领导企业。颇尔公司的业务主要包括两大市场：生命科学与工业市场。公司提供先进的产品以满足生物工程、制药、输血、半导体、水净化、航天以及更多工业市场的需求。公司2005财年的总收入为19亿美元。公司总部位于纽约州East Hills，在全球地区设有众多的分支机构。了解关于颇尔公司的更多信息，请访问网站 http://www.pall.com 。
前瞻性声明
根据《1995年私人证券诉讼改革法案》，本新闻稿中包括有“前瞻性”声明。本新闻稿以公司当前的预期为基础，受到风险与不确定性的影响，可能导致实际业绩与预测业绩存在重大差异。上述风险与不确定性包括但不仅限于：外币汇率波动；新技术能否通过监管批准以及获得市场接受；产品结构、产品定价、利率与原材料成本变化；公司在实施专利、保护专利产品与制造工艺方面能否取得成功以及能否实现成本削减方案预期的费用节省；全球与地区的经济状况以及立法、监管与政治方面的发展；公司在全球市场所面临的国内与国际竞争。公司网站www.pall.com以及公司提交给美国证券交易委员会(U.S. Securities and Exchange Commission)的公司报告中含有与上述因素有关的更多信息。投资者还可以从网站www.sec.gov中免费获得上述报告的副本。
编辑注释：
——公司将会在3月21-23日在INTERPHEX2006举办期间在纽约市Jacob K. Javits会议旅游中心的第1825号展台展示上述技术。
——网站http://www.pall.com/corporate_39401.asp提供相片下载。
联系方式：颇尔公司(Pall Corporation) 媒体联系： Marcia Katz，516-801-9851 Marcia_Katz@pall.com 或者 投资者关系部： Patricia Iannucci，516-801-9848 Pat_Iannucci@pall.com
(BW)(NY-PALL)(PLL) Pall Showcases New Technologies at INTERPHEX2006 to Address Drug Production Challenges
INTERPHEX2006
Booth # 1825
EAST HILLS, N.Y.--(BUSINESS WIRE)--March 21, 2006--
Better process development strategies and scalable technologies are becoming increasingly important as the lines between biotechnology and traditional pharmaceutical companies continue to blur. An increasing number of biotechnology companies are moving beyond discovery to pilot and full-scale drug production. The major pharmaceutical companies continue to increase their investment in R&D for early-stage drug discovery. Moving developments from R&D to full-scale product requires innovative scalable technologies designed for operation under GMP regulations. Pall Corporation (NYSE: PLL) introduces six new technologies at INTERPHEX2006 aimed at helping this converging marketplace bridge the gap between R&D and full-scale production.
These technologies, which cover the range of biopharmaceutical applications throughout each stage of the development and production process, are:
-- the first fully contained filtration system for safe handling of potent pharmaceutical compounds,
-- two advanced hybrid sterilizing grade filters that speed downstream processing for emerging therapies based on high protein concentrations,
-- a new hydraulic chromatography column that automates maintenance and improves safety during drug purification, and
-- two new systems for process optimization with automated data-logging using small protein volumes.
"By providing total fluid management solutions, these new technologies will help drug companies improve the speed, safety and efficiency of the entire development and production process," says Ken Frank, President, Pall BioPharmaceuticals Global. "Whether protecting workers during active pharmaceutical ingredient (API) production, removing inefficiencies in downstream processing, or improving the cost-effectiveness of process modeling, Pall’s new technologies overcome today’s broader processing challenges."
New Product Highlights
While biotech companies have made significant advances in upstream processes that produce high protein concentrations, they are running into bottlenecks downstream because standard filtration technologies do not perform economically at high flow rates in these high titer solutions. The new Supor(R) UEKV and Fluorodyne(R) EX High Flow Sterilizing Grade Cartridge Filters overcome this challenge by delivering exceptionally high throughput to speed production and accelerate time-to-market of new generations of protein-based drugs.
Pall is also announcing new innovations in the chromatography market. Traditional column chromatography systems used to purify biopharmaceuticals require significant downtime and labor to disassemble components for routine maintenance, resulting in lost throughput. In providing an innovative hydraulic lifting mechanism for automatic column disassembly, the new Pall Resolute(R) DAP column chromatography system cuts routine maintenance time by as much as two-thirds. It significantly streamlines cleaning and improves operational safety, giving manufacturers a flexible solution for multi-use operations such as those found in contract drug manufacturing, where quick and safe maintenance between drug batch processing is essential.
Pall addresses the critical need for affordable testing equipment that can reliably process small sample volumes with the introduction of the new Minim(TM) II and Centramate(TM) 500 Tangential Flow Filtration (TFF) systems. The Minim II system enables laboratories to test solutions at ultra-low-volumes to determine true scale-up conditions, a process which could otherwise consume large volumes of precious new drug material during drug discovery and research. The Centramate 500 system moves this concept up to the next scale, being ideal for drug discovery applications that are further along in the development cycle and available in process volumes up to five liters. Both systems facilitate process optimization and reduced development times. The systems also provide automated data-logging to meet increasingly stringent regulatory requirements.
The need for protection against harmful, biologically active, contaminating particulates and catalysts is growing as new and more potent active pharmaceutical ingredients (APIs), such as cytotoxic (cell killing) drugs to treat cancer, are used during pharmaceutical purification processes. To help protect workers and the surrounding environment from exposure to these hazardous compounds, Pall is introducing the GBK Containment System, the pharmaceutical industry’s first all-in-one contained glove bag system that seals securely to a filter housing.
Pall is also promoting the expansion of its operations in Asia at a special media luncheon on Wednesday, March 22 from 12:30 p.m.-2:00 p.m. in Room 1E02 at INTERPHEX2006.
"Our expanding technical and geographic capabilities reflect the company’s commitment to helping customers around the world optimize drug development and production throughout the entire journey to commercialization," adds Frank.
About Pall Corporation
Pall Corporation is the global leader in the rapidly growing field of filtration, separations and purification. Pall’s business is organized around two broad markets: Life Sciences and Industrial. The Company provides leading-edge products to meet the demanding needs of customers in biotechnology, pharmaceutical, transfusion medicine, semiconductor, water purification, aerospace and broad industrial markets. Total revenues for fiscal 2005 were $1.9 billion. The Company headquarters is in East Hills, New York with extensive operations throughout the world. Visit Pall at http://www.pall.com.
Forward-Looking Statement
This release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on current Company expectations and are subject to risks and uncertainties which could cause actual results to differ materially. Such risks and uncertainties include, but are not limited to: fluctuations in foreign currency exchange rates; regulatory approval and market acceptance of new technologies; changes in product mix and product pricing and in interest rates and cost of raw materials; the Company’s success in enforcing its patents and protecting its proprietary products and manufacturing techniques and its ability to achieve the savings anticipated from its cost reduction initiatives; global and regional economic conditions and legislative, regulatory and political developments; and domestic and international competition in the Company’s global markets. Additional information regarding these and other factors is available on the Web at www.pall.com and is included in the Company’s reports filed with the U.S. Securities and Exchange Commission. Copies of such reports can be obtained, without charge, at www.sec.gov.
Editor’s Notes:
-- These technologies will be on display at INTERPHEX2006, Jacob K. Javits Convention Center, New York, March 21-23, 2006, Booth # 1825.
-- Photos are available at http://www.pall.com/corporate_39401.asp.
CONTACT: Pall Corporation Media: Marcia Katz, 516-801-9851 Marcia_Katz@pall.com or Investor Relations: Patricia Iannucci, 516-801-9848 Pat_Iannucci@pall.com
